Comparative pharmacoepidemiological assessment of antianginal, antiplatelet and lipid-lowering drugs in patients with stable angina in outpatient practice in Kursk and Chisinau

Abstract

Aim. To study structure of medical purposes of anti-anginal, antiplatelet and hypolipidemic means at coronary heart disease patients in ambulatory practice of Kursk (Russian Federation) and Chisinau (Republic of Moldova). Materials and methods. During the period from October, 2017 to January, 2018 as a one-stage descriptive research, questioning of doctors of the medical organizations of Kursk and Chisinau was carried out. Questionnaires included questions on pharmacoepidemiological aspects of purpose of antianginal, antiplatelet and hypolipidemic means. Total number of respondents was 132, of them 66 (2 cardiologists and 64 therapists) - in Kursk and 66 (10 cardiologists and 56 therapists) - in Chisinau. Results. Doctors of Kursk and Chisinau have no statistically significant differences in structure of appointments of the main groups of anti-anginal means, antiplatelet and hypolipidemic drugs. The tendency to more frequent use of blockers of calcium channels and nitrovazodilatator among doctors of Chisinau while in structure of appointments of doctors of Kursk some prevalence of a trimetazidin, antiagregants and statines was noted was noted (p>0.05). Leaders in group of beta blockers were bisoprolol and metoprolol in the conditions of the pharmaceutical market of Kursk and Chisinau. Priority of the choice of blockers of calcium channels authentically differed in the considered regions only on a felodipin - in Kursk appointed it to a thicket (p

Keywords

• pharmakoepidemiology
• anti-anginal
• antiplatelet
• hypolipidemic drugs